MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
Organization & Developments: Teva
Parents
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
Children
*Global product portfolio of more than 1,450 molecules and a direct presence in about 60 countries.
*Joint venture with Teva as an alternative allogeneic therapy for patients with blood cancers such as leukemia and lymphoma
*Teva is the world's largest generic drug maker
*Teva, the world's biggest generic drugmaker
*Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics.
*Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis.
2010: Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.
2012: Teva Announces Departure of President and CEO (2012)
2016: Comments On Teva And Generics Stocks - DoctoRx
2016: IBM and Teva extend partnership to put Watson to work on chronic disease management
2017: Teva's stunning list of cuts targets 14K jobs, $3B in costs and plants around the globe
2017: VA_65--Teva Pharmaceuticals USA, Inc. (65IB)_Effective 8/15/2017
2018: On a mission to save Teva from crippling debt, Schultz stands by cost-cutting measures, scrutinizes per product profitability – Endpoints News
2022: Howard University, Teva Pharmaceuticals launch coalition to advocate for equity through digital health
2022: Teva Pharmaceutical Industries Limited 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike_seekingalpha.com
2022: Teva Pharmaceutical: Past Behind And A Promising 2023_seekingalpha.com
2022: Teva Pharmaceutical: Warren Buffett Likely Made A Mistake Selling Shares_ seekingalpha.com
2022: Teva to pay $4.3B to settle opioid epidemic litigation with states
2024: Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight
2024: Duvakitug And Teva's Growth: A Game Changer In Pharma_seekingalpha.com
2024: Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
2024: Teva: Becoming Increasingly Solid, But No Longer Undervalued
2024: Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
2024: Teva's SWOT analysis: stock outlook brightens on legal clarity, biosimilar push
2024: Teva's Transformation: From Generics Leader To Branded Drug Innovator
2025: Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
2025: Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds
5 Basel St. Petach Tikva 49131, Israel
Jumps
*Key People: Teva
Finance & Acquisitions: Teva